COVID-19 Impact on Asia-Pacific Hospitals: Edition 3 L.E.K. Consulting and GRG Health Survey June 25, 2020 Fabio La Mola Stephen Sunderland Rishabh Bhawsar Manan Sethi
Life Sciences & Pharma Special Report Why and How Japanese Life Science Commercial Organizations Can Move Beyond the… May 11, 2020 Japanese healthcare expenditures have reached an unsustainable level, leading to a variety of government measures
Life Sciences & Pharma COVID-19 COVID-19 Therapeutic Research and Development Landscape June 3, 2020 The following materials provide a snapshot of the unprecedented scope and speed of biopharma’s therapeutics research and development (R&D) response to…
Digital Healthcare COVID-19 2020 Asia-Pacific (APAC) Digital Readiness for the Healthcare Sector May 5, 2020 L.E.K. Consulting and Galen Growth conducted a survey of ~90 industry leaders in Q4 2019 to assess the digital readiness of healthcare sectors and…
Life Sciences & Pharma Special Report Weighing the Trade-offs of a Direct Presence in Japan’s Rare and Orphan Drug Market February 20, 2020 In recent years, there has been a marked uptick in the number of rare and orphan companies establishing local operations in Japan to steward their…
Life Sciences & Pharma COVID-19 European Disease Progression Monitor: Edition 8 June 17, 2020 In light of new data surrounding the impact of COVID-19 on the population, health services, pharmaceutical industry and wider economy, L.E.K.’s Healthcare…
MedTech Published Articles Strategic Hospital Priorities in APAC – Emerging Themes and Implications for Medtechs April 1, 2020 With the COVID-19 crisis putting pressure on our healthcare systems, some short-term priorities will have obviously changed.
